Botanical species · safety record

Digitalis grandiflora

The EFSA Compendium of Botanicals holds 23 constituent measurements for Digitalis grandiflora. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Digitalis grandiflora Mill.

23Constituent measurements

0Safety records

10Cited sources

0Licensed products (Canada)

Also recorded as

Digitalis ambigua Murray

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Cardenolide glycosides	Seed	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Digitoxin	Seed	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Gitoxin	Seed	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Lanatoside a	Leaves	Solvent extraction	≤ 80.2 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Lanatoside a	Leaves	Solvent extraction	≥ 74.2 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Lanatoside b	Leaves	Solvent extraction	≥ 43.2 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Lanatoside b	Leaves	Solvent extraction	≤ 44 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Phenylpropanoids	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Strospeside	Seed	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Anthraquinones	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Cardenolides	Leaves	—	≤ 0.61 Percent	Unspecified	No resolvable identifier
Cardenolides	Leaves	—	≥ 0.2 Percent	Unspecified	No resolvable identifier
Cardenolides	Leaves	—	0.3 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Cardiac glycosides	Leaves	—	≥ 0.22 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Cardiac glycosides	Leaves	Solvent extraction	≤ 0.535 Percent	—	No resolvable identifier
Cardiac glycosides	Leaves	Solvent extraction	≥ 0.4 Percent	—	No resolvable identifier
Cardiac glycosides	Leaves	—	≤ 0.388 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Digitoxin	Leaves	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Digoxin	Leaves	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Gitoxin	Leaves	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Lanatoside a	Leaves	—	4.35 Milligram/gram	Unspecified	No resolvable identifier
Lanatoside a	Leaves	Solvent extraction	≤ 0.275 Percent	—	No resolvable identifier
Lanatoside a	Leaves	Solvent extraction	≥ 0.13 Percent	—	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

LETCHAMO, W. EFFECT OF TRACE-ELEMENTS ON CARDIAC-GLYCOSIDES ACCUMULATION IN DIGITALIS-GRANDIFLORA . Planta medica, 1986, no. 5, p. 421-421.
ULUBELEN, A. PRELIMINARY STUDIES EXTRACTION OF GLYCOSIDES FROM DIGITALIS GRANDIFLORA SEEDS . Journal of pharmaceutical sciences, 1964, vol. 53, no. 9, p. 1123-&. DOI
FUJII, Y., IKEDA, Y., YAMAZAKI, M. HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF LANATOSIDES IN DIGITALIS-LUTEA AND DIGITALIS-AMBIGUA LEAVES . Journal of liquid chromatography, 1994, vol. 17, no. 20, p. 4451-4461. DOI
Shchelokova, L. G., Glumov, G. A., Garbuzova, V. M. Content of lanatosides A, B, and C, in Digitalis grandiflora in the cis-Urals. Rastitel'nye resursy, 1975, vol. 11, no. 3, p. 358-62.
CALCANDI, V., CALCANDI, I., LUNGEANU, I. LANATOSID A HAUPTGLYKOSID DER BLATTER VON DIGITALIS GRANDIFLORA MILL. Naturwissenschaften, 1964, vol. 51, no. 10, p. 243-&.
FIEDLER, KR., GISVOLD, O. A PRELIMINARY PHYTOCHEMICAL INVESTIGATION OF DIGITALIS-GRANDIFLORA. Journal of the american pharmaceutical association, 1957, vol. 46, no. 5, p. 317-320.
Grinkevich, N. I., Sorokina, A. A., Kucherov, E. V. Cardiac glycoside and trace element content of Digitalis grandiflora Mill. growing in Bashkiria. Rastitel'nye resursy, 1981, vol. 17, no. 3, p. 406-10.
Baudouin, G., Skaltsounis, A L., Tillequin, F., Koch, M. Lugrandoside: a new phenylpropanoid glycoside from various digitalis species. . Planta medica, 1988, vol. 54, no. 4, p. 321-3. DOI
Imre, Zeliha., Yurdun, Turkan., Cone, Huseyin. Quantitative glucoside composition of the leaves of Turkish Digitalis species. Journal of faculty of pharmacy of istanbul university, 1981, vol. 17, p. 215-28.
Ert�rk, S., Imre, S. Anthraquinones from the roots of digitalis grandiflora. Acta pharmaceutica turcica, 2001, vol. 43, no. 2, p. 73-75.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature